ࡱ> xI  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwyz{|}~Root Entryb.@pYýPerfectOffice_MAIN&SPerfectOffice_OBJECTS,PýPýSummaryInformation(HOh+'Oh+'0  1\TWPC|Times New Roman Regular +)?   4>2  I  .3  TitleofSlide  0j$+' ҄\.#ic 6Times New Roman Regularc    WPCS ~ fg1+ ZK$zBZHZ/w)I\sbshs"|B"XXXX'33' #<S U h~5n?!#b1&')k,-/23A6+9_;,>@kBCF3HKpM8PqSeUFXYZ[u] WPC .$.2  I  .3  cqd9 Z6Times New Roman Regularc` ` ` TRENDScqd9 Z6Times New Roman Regularc cqd9 Z6Times New Roman Regularc        @  in        @cqd9 Z6Times New Roman Regularc cqd9 Z6Times New Roman Regularc` ` ` PSYCHOPHARMACOLOGYcqd9 Z6Times New Roman Regularc ....2  1  .3  ]q@ Z0BernhardMod BT Roman]JOHNF.ABESS,M.D.cqd9 Z6Times New Roman Regularc]q@ Z0BernhardMod BT Roman]        @http://www.abess.comcqd9 Z6Times New Roman Regularc7-2#$%72  I  .3  OBJECTIVE....2  1  .3  INCREASEDAWARENESSOFTRENDS..2  A  .3  PsychotropicsinGeneral..2  A  .3  Anti-depressants..2  A  .3  MoodStabilizers..2  A  .3  Anti-psychotics..2  A  .3  Anxiolytics7-2 !"72  I  .3  ANSWERS....2  1  .3  TOEDUCATIONALCREDITQUESTIONS..2  A  .3  cqd9 Z6Times New Roman RegularcxxxPSYCHOTROPICS:        @          @  INCREASINGUTILIZATION          @  ..2  A  .3  cqd9 Z6Times New Roman RegularcxxxANTIDEPRESSANTS:          @  SSRI>COMBI>TCAs..2  A  .3   cqd9 Z6Times New Roman RegularcxxxSTABILIZERS:         @MORECHOICESTHANLITHIUM..2  A  .3   cqd9 Z6Times New Roman RegularcxxxANTIPSYCHOTICS:         @MOVINGTOATYPICALS..2  A  .3   cqd9 Z6Times New Roman RegularcxxxANXIOLYTICS:         @USENONADDICTINGWHENAPPROPRIATE 7-272  I  .3  PSYCHOTROPICS....2  1  .3  COGNITION-AFFECT-BEHAVIOR..2  A  .3  IncreasingUtilization......2  a  .3  MoreMedicationsAvailable......2  a  .3  SaferMedicationscqd9 Z6Times New Roman Regularcxxx        @  ......2  a  .3  IncreasingUsebyPrimaryCareMDs        @......2  a  .3  DecreasingStigmaandIncreasedAwarenessofBenefits......2  a  .3  BiologicalModelofPsychiatricIllness7-272  I  .3  ANTIDEPRESSANTS....2  1  .3  TRI-CYCLICSTRADITIONALANTI-DEPRESSANTS..2  A  .3  IMIPRAMINE-TOFRANIL..2  A  .3  AMITRYPTILENE-ELAVIL..2  A  .3  DESIPRAMINE-NORPRAMIN..2  A  .3  NORTRYPTILENE-PAMELAR..2  A  .3  PROTRYPTILENE-AVENTYL7-2   72  I  .3  ANTIDEPRESSANTS....2  1  .3  ԀDISADVANTAGESOFTRI-CYCLICS..2  A  .3  FatalCardiacArrythmias..2  A  .3  StatusEpilepticus..2  A  .3  OrthostaticHypotension..2  A  .3  Constipation..2  A  .3  WeightGain..2  A  .3  BlurredVision..2  A  .3  MemoryImpairment7- 2 WXY72  I  .3  ANTIDEPRESSANTS....2  1  .3  MAOINHIBITORS..2  A  .3  PARNATE..2  A  .3  NARDIL7- 2 Z[\72  I  .3  ANTIDEPRESSANTS....2  1  .3  DISADVANTAGESOFMAOIs..2  A  .3  HYPERTENSIVECRISES..2  A  .3  RISKOFSTROKES..2  A  .3  RIGIDDIETW/OTYRAMINE..2  A  .3  WEIGHTGAIN..2  A  .3  ORTHOSTATICHYPOTENSION7- 2    72  I  .3  ANTIDEPRESSANTS....2  1  .3  SELECTIVESERONTONINRE-UPINHIBITORSTHENEWGENERATIONBEGINS..2  A  .3  Fluoxetine-Prozac..2  A  .3  Paroxetine-Paxil..2  A  .3  Sertraline-Zoloft..2  A  .3  Fluvoxamine-Luvox7- 2 72  I  .3  ANTIDEPRESSANTS....2  1  .3  SELECTIVESERONTONINRE-UPINHIBITORSADVANTAGES..2  A  .3  SafetySafetySafety..2  A  .3  BetterTolerated7- 2 72  I  .3  ANTIDEPRESSANTS....2  1  .3  SELECTIVESERONTONINRE-UPINHIBITORSDISADVANTAGES..2  A  .3  EffectivenessforSevereDepression..2  A  .3  SexualFunctionProblems7- 2 72  I  .3  ANTIDEPRESSANTS....2  1  .3  MULTI-NEUROTRANSMITTERSYSTEMSSECONDPHASEOFNEWGENERATION..2  A  .3  BUPROPRION-WELLBUTRIN..2  A  .3  VENLAFAXINE-EFFEXOR..2  A  .3  NEFAZADONE-SERZONE..2  A  .3  MIRTAZAPINE-REMERON7- 2 72  I  .3  ANTIDEPRESSANTS....2  1  .3  MULTI-NEUROTRANSMITTERSYSTEMADVANTAGES..2  A  .3  ENHANCEDEFFECTIVENESS..2  A  .3  SAFETY..2  A  .3  BETTERTOLERATED7-2 72  I  .3  ANTIDEPRESSANTS....2  1  .3  MULTI-TRANSMITTERSYSTEMSDISADVANTAGES..2  A  .3  NOTALWAYSEFFECTIVE..2  A  .3  RATIOSMAYNOTBEIDEAL7-2 72  I  .3  ANTIDEPRESSANTS....2  1  .3  CUSTOMIZEDANTI-DEPRESSANTTHERAPYCOMBINATIONTHERAPY..2  A  .3  Buproprion+SSRI..2  A  .3  Buproprion+Buspirone..2  A  .3  Buproprion+SSRI+Buspirone..2  A  .3  Venlafaxine+Buproprion..2  A  .3  Desipramine+SSRI..2  A  .3  Desipramine+Buspirone7-2&]72  I  .3  ԀANTIDEPRESSANTS....2  1  .3  MATCHINGPATIENTPROFILETOMEDICATIONS7-2^_`72  I  .3  ANTIDEPRESSANTS....2  1  .3  TREND..2  A  .3  StartfirstwithNewGeneration..2  A  .3  ..2  A  .3  UseCombinationofNewGenerationforMoreResistantCases...2  A  .3  ..2  A  .3  TCAsandMAOIsusedlast.7-2'()72  I  .3  MOODSTABILIZERS....2  1  .3  OLDESTTOMOSTRECENT..2  A  .3  LITHIUM..2  A  .3  CARBAMAZEPINE-TEGRETOL..2  A  .3  VALPROATE-DEPAKOTE..2  A  .3  CALCIUMIONCHANNELB...2  A  .3  GABAPENTIN-NEURONTIN..2  A  .3  LAMOTRIGINE-LOMICTAL;1 2*+, ;2  I  .3  MOODSTABILIZERS....2  1  .3  AJPjan98:MoodStabilizerCombinations:AReviewofSafetyandEfficacyMarleneP.Freeman,M.D.,andAndrewL.Stoll,M.D...2  A  .3  LithiumwasfirstrecognizedastreatmentformaniabyJohnCadein1949.ItcameintouseintheU.S.forbipolardisorderinthe60's...2  A  .3  ;12-./ ;2  I  .3  MOODSTABILIZERS....2  1  .3  AJPjan98:MoodStabilizerCombinations:AReviewofSafetyandEfficacyMarleneP.Freeman,M.D.,andAndrewL.Stoll,M.D...2  A  .3  Carbamazepinewasfirstusedforbipolardisorderinthe1970's...2  A  .3  ..2  A  .3  ValproatewasjustrecentlyapprovedbytheFDAforuseinbipolardisorder.7- 20S172  I  .3  MOODSTABILIZERS....2  1  .3  TIMEFRAME..2  A  .3  cqd9 Z6Times New Roman Regularc444GabapentinandLomotriginearenewanticonvulsantsthatarebeingfoundinresearchtohavebenefitsforpatientswithbipolardisorder.O \AZ"Arial RegularO444Ԁ7- 2TUV72  I  .3  MOODSTABILIZERS....2  1  .3  TREND..2  A  .3  INCREASINGNUMBERSOFAGENTSAREAVAILABLETHOUGHLITHIUMREMAINSDRUGOFFIRSTCHOICE7- 223472  I  .3  ANTIPSYCHOTICS....2  1  .3  TYPICALS..2  A  .3  CHLORPROMAZINE1950's..2  A  .3  OTHERS..2  A  .3  HALOPERIDAL1960's7- 256772  I  .3  ANTIPSYCHOTICS....2  1  .3  SIDEEFFECTSOFTYPICALS..2  A  .3  TREMOR..2  A  .3  STIFFNESS..2  A  .3  COGWHEELING..2  A  .3  ACUTEMUSCLEDYSTONIA..2  A  .3  TARDIVEDYSKINESIA..2  A  .3  INEFFECTIVENEGATIVESXs7- 289:72  I  .3  ANTIPSYCHOTICS....2  1  .3  ATYPICALS..2  A  .3  CLOZAPINE-CLOZARIL..2  A  .3  RISPERDONE-RISPERDAL..2  A  .3  OLANZAPINE-ZYPREXA..2  A  .3  QUIETEPINE-SEREQUEL7-2;<=72  I  .3  ANTIPSYCHOTICS....2  1  .3  ADVANTAGESOFATYPICALS..2  A  .3  REDUCEDTREMOR..2  A  .3  REDUCEDSTIFFNESS..2  A  .3  REDUCEDCOGWHEELING..2  A  .3  REDUCEDMUSCLEDYSTONIA..2  A  .3  REDUCEDTARDIVEDYSKINESIA..2  A  .3  EFFECTIVEforNEGATIVESXs7-2>?@72  I  .3  ANTIPSYCHOTICS....2  1  .3  DISADVANTAGESOFATYPICALS..2  A  .3  EXPENSE-$..2  A  .3  LONGTERMEFFECTS-?7-2ABC72  I  .3  ANTIPSYCHOTICS....2  1  .3  TREND..2  A  .3  ԀTYPICALcqd9 Z6Times New Roman Regularc        @  toward        @cqd9 Z6Times New Roman Regularc444ATYPICAL;12 DEF ;2  I  .3  ANXIOLYTICS....2  1  .3  PRE-BENZODIAZEPINEERA..2  A  .3  GLUTETHIMIDE..2  A  .3  MEPROBAMATE..2  A  .3  BARBITURATES........2(  1  )3  cqd9 Z6Times New Roman RegularcXXX7- 2!GHI72  I  .3  ANXIOLYTICS....2  1  .3  DISADVANTAGESOFPREBENZODIAZEPINEERAAGENTS..2  A  .3  LOWTHERAPEUTICINDEX..2  A  .3  TOLERANCEQUICKLY..2  A  .3  HIGHLYABUSED7- 2"JKL72  I  .3  ANXIOLYTICS....2  1  .3  BENZODIAZEPINEERA..2  A  .3  DIAZEPAM-VALIUM..2  A  .3  CHLORDIAZEPOXIDE-LIBRIUM..2  A  .3  CHLORAZEPATE-TRANZENE..2  A  .3  OXAZEPAM-SERAX..2  A  .3  ALPRAZOLAM-XANAX..2  A  .3  LORAZEPAM-ATIVAN7-  2#abc72  I  .3  ANXIOLYTICS....2  1  .3  ADVANTAGESOFBENZODIAZEPINES..2  A  .3  SAFERSAFERSAFER..2  A  .3  NOTOLERANCEDEVELOPS7-!2$def72  I  .3  ANXIOLYTICS....2  1  .3  DISADVANTAGESTOBENZODIAZEPINES..2  A  .3  SOMEABUSE..2  A  .3  SOMERISK7-"2% MNO72  I  .3  ANXIOLYTICS....2  1  .3  CURRENTUSAGE..2  A  .3  BENZODIAZEPINES..2  A  .3  BUSPIRONE-BUSPAR..2  A  .3  BETABLOCKERS..2  A  .3  5HT2ANTAG&5HTREUP..2  A  .3  ANTIHISTAMINES7- #2&!PQR72  I  .3  ANXIOLYTICS....2  1  .3  TREND..2  A  .3  ADDICTIVE        @  cqd9 Z6Times New Roman Regularc@@@        @  towardcqd9 Z6Times New Roman Regularc444        @  UNADDICTIVE..2  A  .3  ..2  A  .3  ABUSEDcqd9 Z6Times New Roman Regularc@@@        @  towardcqd9 Z6Times New Roman Regularc444        @  NONABUSED..2  A  .3  ..2  A  .3  LETHALcqd9 Z6Times New Roman Regularc@@@        @  towardcqd9 Z6Times New Roman Regularc444        @  NONLETHALFS&T>7X(B $VBackground TitleBullet ChartTextOrg ChartData ChartCombinationWPCXX81%13.TMP-3'XXXX,,,,5/ @1  ?"""333DDDUUUfffwwwMf33MMffM&f3@MYfs3Mf̙ٳMMff3Mf&M3f@MYfs3MfMf33MMffM&f3@MYfs3MfMMff3Mf&M3f@MYfs3MfMf33MMff&M3f@MYfs3Mf̙ٳMMff3MfM&f3@MYfs3MfpJ&T0Z4`8f<k@pEzJ̉]٘p槂Ħϰֿfffffffffrffffrffffff9WPCXX81%\0t3'XXXX,,,,5/ @1  ?"""333DDDUUUfffwwwMf33MMffM&f3@MYfs3Mf̙ٳMMff3Mf&M3f@MYfs3MfMf33MMffM&f3@MYfs3MfMMff3Mf&M3f@MYfs3MfMf33MMff&M3f@MYfs3Mf̙ٳMMff3MfM&f3@MYfs3MfpJ&T0Z4`8f<k@pEzJ̉]٘p槂Ħϰֿfffffffffrffffrffffff9"0m$0m$W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?   4=2  I  .3  TitleofShow  0m$+' k.#kc 6Times New Roman Regularc         @  Q Qc 6Times New Roman Regularc         @  TitleofShow+'13 `0013"E0v0vW` 6Times New Roman Regular -@W` 6Times New Roman Regular -@W` 6Times New Roman Regular -@W` 6Times New Roman Regular -@W` 6Times New Roman Regular -@W` 6Times New Roman Regular -@)?  f 4@2  I  .3  SubtitleofShow  0v+' @.kc 6Times New Roman Regularc        @  Q Qc 6Times New Roman Regularc        @  SubtitleofShowWPC%XX81%_0?#ل3'XXXX,,,,5/ @1  ?"""333DDDUUUfffwwwMf33MMffM&f3@MYfs3Mf̙ٳMMff3Mf&M3f@MYfs3MfMf33MMffM&f3@MYfs3MfMMff3Mf&M3f@MYfs3MfMf33MMff&M3f@MYfs3Mf̙ٳMMff3MfM&f3@MYfs3MfpJ&T0Z4`8f<k@pEzJ̉]٘p槂Ħϰֿfffffffffrffffrffffff9"Ԅ0j$0j$W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6     @  Q Qc 6Times New Roman Regularc         @  TitleofSlide+'13 `ӄ0013"ք0w0wW` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?  f 4A2  I  .3  SubtitleofSlide  0w+' Մ@.lc 6Times New Roman Regularc        @  Q Qc 6Times New Roman Regularc        @  SubtitleofSlide+'"؄y 0y 0W`44 6Times New Roman Regular +W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !/  f 4\2  I  .3  FirstItem2  A  .3  subitem2  II  .3  SecondItem2  A  .3  subitem2  III  .3  ThirdItem2  IV  .3  FourthItem  y 0+' ׄ@y . c 6Times New Roman Regularc        @W Wc 6Times New Roman Regularc444        @          @0X..        @FirstItemc 6Times New Roman Regularc        @  ,..,        @0..        @subitemc 6Times New Roman Regularc444        @          @0X..        @SecondItemc 6Times New Roman Regularc        @  ,..,        @0..        @subitemc 6Times New Roman Regularc444        @          @0X..        @ThirdItemc 6Times New Roman Regularc444        @0X..        @FourthItemWPC3XX81%?#P0?#3'XXXX,,,,5/ @1  ?"""333DDDUUUfffwwwMf33MMffM&f3@MYfs3Mf̙ٳMMff3Mf&M3f@MYfs3MfMf33MMffM&f3@MYfs3MfMMff3Mf&M3f@MYfs3MfMf33MMff&M3f@MYfs3Mf̙ٳMMff3MfM&f3@MYfs3MfpJ&T0Z4`8f<k@pEzJ̉]٘p槂Ħϰֿfffffffffrffffrffffff9"0j$0j$W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?   4>2  I  .3  TitleofSlide  0j$+' \.#ic 6Times New Roman Regularc         @  Q Qc 6Times New Roman Regularc         @  TitleofSlide+'13 `0013"0w0wW` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?  f 4A2  I  .3  SubtitleofSlide  0w+' @.lc 6Times New Roman Regularc        @  Q Qc 6Times New Roman Regularc        @  SubtitleofSlide+'"?=P0?=P0W`44 6Times New Roman Regular +W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !)  f 42  I  .3  Thisisthefirstitem.Thisistheseconditem.Thisisthethirditem.Thisisthefourthitem.  ?=P0+' =?/c 6Times New Roman Regularc        @  Q Qc 6Times New Roman Regularc444        @  Thisisthefirstitem.Thisistheseconditem.Thisisthethirditem.Thisisthefourthitem.WPC(XX81%- 0?#T3'XXXX,,,,5/ @1  ?"""333DDDUUUfffwwwMf33MMffM&f3@MYfs3Mf̙ٳMMff3Mf&M3f@MYfs3MfMf33MMffM&f3@MYfs3MfMMff3Mf&M3f@MYfs3MfMf33MMff&M3f@MYfs3Mf̙ٳMMff3MfM&f3@MYfs3MfpJ&T0Z4`8f<k@pEzJ̉]٘p槂Ħϰֿfffffffffrffffrffffff9"-0j$0j$W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?   4>2  I  .3  TitleofSlide  0j$+' +\.#ic 6Times New Roman Regularc         @  Q Qc 6Times New Roman Regularc         @  TitleofSlide+'13 `,0013"/0w0wW` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?  f 4A2  I  .3  SubtitleofSlide  0w+' .@.lc 6Times New Roman Regularc        @  Q Qc 6Times New Roman Regularc        @  SubtitleofSlide+' S- 0- 0Q`@@ 0Times New Roman Bold !    2  I  .3  President..2  A  .3  ManagerA....2  1  .3  Employee1....2  2  .3  Employee2....2  3  .3  Employee3..2  B  .3  ManagerB....2  1  .3  Employee4....2  2  .3  Employee5....2  3  .3  Employee6 - 0+'3 0{{+'13 1''.+%13 2] 0Times New Roman Bold]        @    President.%'1 3 ; ;  +'13 4{ = ={ +%1 5.+%13 6{ ?_] 0Times New Roman Bold]ooo        @    ManagerA.%'1 7Q!; (; (Q!+'13 8 ' ' +%1 9O$O$.+%13 : '_] 0Times New Roman Bold]ooo        @    ManagerB.%'1 ;  i i +'13 <   +%1 =    .+%13 >2 d ] 0Times New Roman Bold];;;        @    Employee1.%'1 ?9 DDi 9 i +'13 @    +%1 A  .+%13 B 2 d ] 0Times New Roman Bold];;;        @    Employee2.%'1 C`kki `i +'13 D    +%1 E   .+%13 F2 d ] 0Times New Roman Bold];;;        @    Employee3.%'1 G  i i +'13 H# .  . # +%1 IO$ O$ ( ( .+%13 J#2 0 d ] 0Times New Roman Bold];;;        @    Employee4.%'1 K!''i !i +'13 LI! T' T' I! +%1 MN$ N$ .+%13 NI!2 V'd ] 0Times New Roman Bold];;;        @    Employee5.%'1 O(..i (i +'13 Pp( {. {. p( +%1 QO$ u+ u+ .+%13 Rp(2 }.d ] 0Times New Roman Bold];;;        @    Employee6WPCBXX81% 0?#3'XXXX,,,,5/ @1  ?"""333DDDUUUfffwwwMf33MMffM&f3@MYfs3Mf̙ٳMMff3Mf&M3f@MYfs3MfMf33MMffM&f3@MYfs3MfMMff3Mf&M3f@MYfs3MfMf33MMff&M3f@MYfs3Mf̙ٳMMff3MfM&f3@MYfs3MfpJ&T0Z4`8f<k@pEzJ̉]٘p槂Ħϰֿfffffffffrffffrffffff9"0j$0j$W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?   4>2  I  .3  TitleofSlide  0j$+' \.#ic 6Times New Roman Regularc         @  Q Qc 6Times New Roman Regularc         @  TitleofSlide+'13 `0013"0w0wW` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?  f 4A2  I  .3  SubtitleofSlide  0w+' @.lc 6Times New Roman Regularc        @  Q Qc 6Times New Roman Regularc        @  SubtitleofSlide+'  0 0#?Y@4@#?Y@4@#?@? )| )|   22226ffffffֿp= ף(\?TQ  +  +  +  +   +  +  +?  +  +   +    ) |   ) |   ) |   ) |  )|  )|  )|  )|  )|?  )|  )|  )|  )|  )| 49UqW`` ` 6Times New Roman Regular )|  )|fW`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|fW` 6Times New Roman Regular )|  )|W` 6Times New Roman Regular )|  )|W ` 6Times New Roman Regular ) |  ) | W  6Times New Roman Regular ) |  ) | W ` 6Times New Roman Regular ) |   ) | C A"Arial Regular ) |   ) |   // /Title of ChartLegendd B@1st Qtr2nd Qtr3rd Qtr4th QtrNorth# Z2AU@South# 2(-F@East# (@West# -  0+'1 ))AA.+%13 Yc 6Times New Roman Regularc        @    North.+%13 gg.+%13 c 6Times New Roman Regularc        @    South.+%13 .+%13 $c 6Times New Roman Regularc        @    East.+%13   !!.+%13 #b%c 6Times New Roman Regularc        @    West.1   >L     0  0  L  0 R)L 1  } 0} ˆ  0 Èw D 0D Ĉ  0) ňL   ƈL a  Lj| L 7' ) Ȉ^.f  f  Ɉ f  X ʈ, X  ˈX X  ̈+   ͈ %13 Έ  S13 ψ  S S13 ЈS S ш  13 ҈~  ~13 ӈU~ Ԉ# $ $#V13 ՈT # #VTV13 ֈ#V$+ TV ׈, l- l-,13 ؈)( , ,)(13 و,l-))(1 ڈd ;9 ;2d13 ۈ d d 13 ܈d;2 2  ݈: 9 :13 ވ : :13 ߈: " "9 ""?13  " "??13 "?"|? * +9 +*<13 {& * *<{&<13 *<+R'{&<1 ,   ) 13 J , , ) J ) 13 )  ! J )  , b b 13  , ,   13  b   a , 8! 8!Ma 13 , a , a 13 a 8!MM 7), * * 7) 13 $, 7), 7) $ 13 7) * % $ 1  y   13 y  y   13   s    y  6  13 qy y  q 13  6 I6 q  y  h  13 Gy y  G 13  h h G  'y _( _(2'13 #y 'y '#13 '_(2#2#%13 e L e .1  'c 6Times New Roman Regularc        @    1stQtr.1 ;L ;.1 'c 6Times New Roman Regularc        @    2ndQtr.1 L .1 t'c 6Times New Roman Regularc        @    3rdQtr.1 $L $.1 J#&'c 6Times New Roman Regularc        @    4thQtr.1 L iL .1   c 6Times New Roman Regularc        @    0.1  i .1    c 6Times New Roman Regularc        @    20.1  i.1   sc 6Times New Roman Regularc        @    40.1  wiw.1   c 6Times New Roman Regularc        @    60.1 i.1  I :c 6Times New Roman Regularc        @    80.1 >i>.1  c 6Times New Roman Regularc        @    100WPC VXX81% 0?#^3'XXXX,,,,5/ @1  ?"""333DDDUUUfffwwwMf33MMffM&f3@MYfs3Mf̙ٳMMff3Mf&M3f@MYfs3MfMf33MMffM&f3@MYfs3MfMMff3Mf&M3f@MYfs3MfMf33MMff&M3f@MYfs3Mf̙ٳMMff3MfM&f3@MYfs3MfpJ&T0Z4`8f<k@pEzJ̉]٘p槂Ħϰֿfffffffffrffffrffffff9"Y0j$0j$W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?   4>2  I  .3  TitleofSlide  0j$+' W\.#ic 6Times New Roman Regularc         @  Q Qc 6Times New Roman Regularc         @  TitleofSlide+'13 `X0013"[0w0wW` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +W` 6Times New Roman Regular +)?  f 4A2  I  .3  SubtitleofSlide  0w+' Z@.lc 6Times New Roman Regularc        @  Q Qc 6Times New Roman Regularc        @  SubtitleofSlide+' ]: : W` 6Times New Roman Regular +W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !W 6Times New Roman Regular !/  f 4\2  I  .3  FirstItem2  A  .3  subitem2  II  .3  SecondItem2  A  .3  subitem2  III  .3  ThirdItem2  IV  .3  FourthItem  : +' \@: p c 6Times New Roman Regularc        @W Wc 6Times New Roman Regularc        @          @0..        @FirstItemc 6Times New Roman Regularc        @  ..        @0..        @subitemc 6Times New Roman Regularc        @          @0..        @SecondItemc 6Times New Roman Regularc        @  ..        @0..        @subitemc 6Times New Roman Regularc        @          @0..        @ThirdItemc 6Times New Roman Regularc        @0..        @FourthItem+' V 0 0#?Y@4@#?Y@4@#?@? )| )|   22226ffffffֿp= ף(\?TQ  +  +  +  +   +  +  +?  +  +   +    ) |   ) |   ) |   ) |  )|  )|  )|  )|  )|?  )|  )|  )|  )|  )| 49UqW`` ` 6Times New Roman Regular )|  )|fW`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|W`ee 6Times New Roman Regular )|  )|fW` 6Times New Roman Regular )|  )|W` 6Times New Roman Regular )|  )|W ` 6Times New Roman Regular ) |  ) | W  6Times New Roman Regular ) |  ) | W ` 6Times New Roman Regular ) |   ) | C A"Arial Regular ) |   ) |   // /Title of ChartLegendd  i@1st Qtr2nd Qtr3rd Qtr4th QtrNorth# Z2AU@South# 2(-F@East# (@West# -  0+'1 n"n&r &r ".+%13 v!"#c 6Times New Roman Regularc        @    North.+%13 $"$&%&%".+%13 &"&)c 6Times New Roman Regularc        @    South.+%13 nnr r .+%13 v!#c 6Times New Roman Regularc        @    East.+%13 $$%%.+%13 &&)c 6Times New Roman Regularc        @    West.1 H HH  H H 0 0  H H 0 ,H 1 V H 0 dH 0 rH 0 H 0)  VH "   #H *'   9(H + )  4/ o   o o] \.| |  |  -    (%13  = f! f! |13 = = ||13  |f!.| k%= % %k%`13 3#= k%= k%`3#`13 k%`%#3#` )= I* I*8)13 '= )= )'13 )I*8(8' N.= . .FN.13 ,= N.= N.,13 N..F,F,1 ! ! 13  ! ! 13  !  U !$ $ $ $13 "Z" $ $Z"13 #$$ " Z" $) q) q))C13 %& ) )C&C13 &)Cq)8'&C 'v- - -!v-13 (=+ v- v-=+13 )v--!+!=+1 *I V  I 13 + I I  13 ,I  |   -# '$V '$k#13 .! # #!13 /#'$k!k! 0,( (V (r,(%13 1% ,( ,(%%%13 2,(%(r_&r%% 3, -V -d , 13 4d* , , d* 13 5, -d *d d* 1 6po   pv 13 78o po pv 8v 13 8pv   8v  9"o N# N# "} 13 : o "o "} } 13 ;"} N# ! }  <S'o ' ' S' 13 =%o S'o S' % 13 >S' ' % %  ?+o 1, 1,[+13 @)o +o +)13 A+1,[)[)%13 BH  .1 C*. c 6Times New Roman Regularc        @    1stQtr.1 D!H ! .1 E*,#. c 6Times New Roman Regularc        @    2ndQtr.1 F&H & .1 Gw$*'. c 6Times New Roman Regularc        @    3rdQtr.1 Hr*H r* .1 I(*+. c 6Times New Roman Regularc        @    4thQtr.1 JH YH .1 K  c 6Times New Roman Regularc        @    0.1 LV YV .1 M  c 6Times New Roman Regularc        @    20.1 NdYd.1 O c 6Times New Roman Regularc        @    40.1 PrYr.1 Qc 6Times New Roman Regularc        @    60.1 RY.1 Sc 6Times New Roman Regularc        @    80.1 TY.1 Uc 6Times New Roman Regularc        @    100$&>dQU!V"V@V_V|V!V!V!V!WW!@W!aW!W!WWWWX7X!XX!yX!X!XX!X!Y!=Y!^Y{Y!Y!Y!Y!Y!CANYON.MIDTHEMIC~1.WAVTADA.WAVCHORD.WAVCHIMES.WAVZION.WAVWHITETRE.WAVWHITECLO.WAVSUNSETRK.WAVSUNSETBG.WAVSTREAM.WAVSEASNAKE.WAVROCKGRAS.WAVMUSICAOP.WAVTHEMIC~1.WAVTADA.WAVDING.WAVCHORD.WAVCHIMES.WAVZION.WAVWHITETRE.WAVWHITECLO.WAVSUNSETRK.WAVSUNSETBG.WAVSTREAM.WAVSEASNAKE.WAVROCKGRAS.WAVMUSICAOP.WAVTHEMIC~1.WAVZION.WAVWHITETRE.WAVWHITECLO.WAVSUNSETRK.WAVSUNSETBG.WAVROCKGRAS.WAVMThdMTrkQg@XYQbC1-P91 Synth PadsC2-P28 Rhythm Guit.C3-P1 Acous. PianoC4-P34 Elec. BassC5-P30 Dist. Guitar C6-P10 Glock. C10-Drums 1991Passport Designs, Inc.Produced By TheMusic Data Company C13-P86-SynthC14-P2-Rhythm Guit C15-P3-Melody Canyon Music C16-Drums WZS@]B[c@@@@Oc[M ! a]2[k{[C[ZVg[g 1r`[B- *$cNTg P tk, @ @ F0T $O V[RO<[LT0V4>T"V[O1bO.V1T[),[TVOOc[cTaV^vOT V[dT;[>V4OATTVO[~V<T.OI[K6T [ V OVg[gOcT^nTOV[hV.T:[/OL0T @V[O  2@@T'V6@O2@[?@0TV[OT^V^[gOfnTVO[hT6[.OGV<4T V[OT;OFVI[L(T*V[OT`OgVf[i\TVO[vT/V9O<,T OV6[gTfVgOgvTVO[^[.VDT9OL,TOV[([gOcEVgTg(EFTO V[RV4T0O<[L>T"V[OrO.TV1[),[TVO[cOcTaEV^*ELOT V[dOAT;V4[>TTVO[~V<OIT.[K6T [ V OEOcVgT^[g&EHTOV[hT:[/V.OL0TV[O T'O2V6[?0TV[OOfT^V^[gE&EHTVO[h[.V<T6OG4T V[OVIT;OF[L(T*V[OVf[iT`EOg(E4TVO[vO<T/V9,T OV6Vg[gOgTfE(ENTVO[^[.T9OLVD,TOV[(+a0`$g[g#sE0c1|$f00&E$^+YO^V[T[($6[R[Lh[#F1:[),[D[cE*Eb[d[>r[~[K@[0E[g+ E$"+ $6[h$n#s+j[/7a $+a #<[`7+[?+6[*-j#v$n9`E[g$-aE"#@[^- [. -N[9[LT[E[i(ER[fE[g(Ej[^[.H[($i#w+fE0f[g$n$`+]E@$6[R[Lh[#[),[D[cE*Eb[d[>r[~[K@[0E[g&E+$+$*[@0($n7i+j#w[/ $+a#D[ +[? +:[ 7#w-jE9g$n[g$-aE#P[\- [.-9:[4X(i (`h[P( ("42c[K&c&[<[t&& 2$\#k$b0NE$d[g$#E@$$[f0`#q+^$n[/if[$$f#[?F[*E[g&Eb[h[.Z[[LT[[iE(ER[f[gE(Ej[*TV[. T[VfV[4Ot$n#vE[g$$EP#&[R[Lh[[),[*T[c$nE#w $ [TY[a#Eb[d[>r[~0#u/[K$m$#/0"[tT.[-}$^#l+~[gEV$+-#E [ZT^VZ]]g+,[b+{-z[/-+H[ $j0i[?@f9$n+g#w*z+^$a0[*"$[gE&ER#[h*x[.>9*[[LT[[i*E(E*<[f[gE*(E@+$ *+$H[ 0RGi$n[.#r+j7d $# +a[7+ *E[g+GE*h[R[L-j9fHg#w$n-a $*#,[*[)&-[-*&9H|[cE*Eb[d*[>6*<[~[K@[0E*[g&E*T[h[/f[ *#w@j1z$n$a[?$j+g0d+^2*["$E[g&EF#[V1*[..*,[<][VR[LT[E[i*(E*@[fE[g*&+E+$$*Z[0:@"#v+j7i$l[.Gi $+a#$[G(+E*[g+ 7 E*n[R[LHi-a$n-j#w9f$@#[--*[)9H[ *60`E[c0iLj/];^/f*<2*<[B//6J-V9U[K-^Hc;<[\--09H +\7^[g*#r$hG\E+d$#E *X[++"G7"5g$j[/Eg#v)i)`>$"[#[?*4*)) [ 5"Ep)` [gEiE)i5g&Eb[&) )5E*[6VF\*c*[.6*$[z*+^*F67T[L+gGZT[$++$7"G*(`(iCg#v*4ZE$b[i$E *#4[J4((C&^2cA^&V &&2A:$R$Z0a*@fE[g$c#o$#E*2$$&[0@0&#w+]$n>fi[.`6[<$l#*E[g(E*f[R[Lh[[)*,[ *8E[c*Eb[d[>*|4*>[~[K@[0E*[g&E*R[h[/f[#w$m,$L#*[?6*[*E[g&Eb[h[.*4*&[[L#w$l$&#[*[iE(E *F[v#q$i$#T$n[g#k*E$E#*\[^[.0[">V[]T$mT\O`V`i9{[d` Oc$+gv9xg.$jbJ^$ b01t$n`yH`>$`HP1f0`//0L0m/{./02$e-$ C][-X[p$i$`)++)T+$l)$&)+RCHOJf[TVO01|Fx$mMc)iYe)NFEVMVHOOP$4Yeh1(@XFxFNMEHBMLTFcFHQCULVZ@j$nFc&v$F$&@H&(LL:JTGUJSJ@F~F)GJCJ6FnHX$f)EXHVATF $:Fr'a'S*F&@FvFXFl$j $ FZFp&v*FJ&(AO'HE$m $f$nFz$F8H@'^LXCV&jL_HVFn&UF@D$mFl&F$@$F|F&CLHDLXJYFl GZJU FJG6$nFr&vFJ$\&jEUHSH^RE&H&H)jFxGR )SGX>ZCTF@<$fFnF"$@"Fn FvG>C2FF`Gz$jE^Fp $L0@2FzF<'C7>:F'6$f&jFOPF7P>L<.CFFX$jFp $ FZFp&v(F&,$m $f$nF$FZFpFXEQs$mF~V`T^Oi[j FE$4QNOTV[CSV;[?T:O$\O[VTXHR(T5PcOV?[P[OVT|JI.Vc[iT`OiE~Q~"EQh[VTO&OY2O)V=[4$nT$&v$$C&OV[HJT&OdV1[9T?PgO)PO[TV&Qv[gET^V^OgQEj[TOVX$fV.T/Q}O([<OVTVVV[^Q$O V[TTOTV[8&OTO [ QV. OQ[V T0&OgVYVd[iP`OVETgTO[[PEBO[VT"[OVTXVC[?T:O2QvO^V]T[[]Q4[VO T[?QV;O7$jTA $QO[TV"[[gTgVg&vEOgPpTVPEO&&2[OVT\[IQs$mO?VL&^TD $QTO[V"&[d&gVgQTf$nEOc$ QEb[OTV`T:V9PlO:[KP&TV[O*FxQ1|)iM\$mF)VE^M^HVOX$Q12@XFxFNMEH\FcMFDC]HYL^Le@j&vFc$n$$F&@2&"H>LL^J[G]@J^xF~F)FCGJ6JJH^Fn$fE`H^A\F $:Fr'a'[)&F&@FvFXFl$j $ FZ&vFp*FJ&$AO' HE$m $fFz$n$F>H:'^L`C^&jFnLdH^&]F@D$mFl&F$@$F|F&CLH8LdFlJa GaJ] FJG6Fr&v$nJF$\&jH[E]HdRE&HxH& )jGTFx )[>aG`C\F@<$fFnF"$@"Fn FvG>C2FFVGEdFp$j $<\E`FZ&vFxFE< &:ErC\$m;^C`$<;C*F|$n$F.)JC)HA^9a$jFbA^0]F@HFj$m0F$$@FxFA$9AFn@^F7`@^0@($n&vFv$$ F@H&dF|FXFl$fF $:Fn$FT0@2FzFC.'7>:F'6F$fO\&jF>T7X<^&V$@4Fg@FX7,><.CFFXFp$j $ FZ&vFp(F&,$m $f$nF$FZFpFX[jV`T^$mEOiQ}F~ FE$*QXOT[VCST:V;[?O$\O[VTXHR(V?T5P_O[P[OVT|JI.Oi[iVcQ~E~T`"EBQ,[VOT&OY2&vV=[4$nO)T$$$C&O[VHJT&Od[9V1T?PiO)P O[TV&T^OgEV^[gQqQEj[TOVXT/O($f[<V.Q~OVTVVV[^ Q$O V[TTOTV[8O V.PiT[ P O [V T0&VYOVOg[iVdETgQwTO[[QEBOVT["[OVTXQ}T:[?O2VCO^T[V][]Q0[VO T[?PbTAO7$jV; $ P,O[TV"[[g&vEOgTgQ~VgTVEOQ&2[OVT\&^VLO?TD$m[I $*TO[V&,&^Q}Oc$nTf&g[dVgE$EQ\[OTV`T:@PiO:[KV9P&TVO[*$c[gVgQOc1rTgnT $O V[RV4[LT0O<>T"V[O1Q^O.T[)V1,[TVOTaV^Oc[cFO0OT V[dT;OA[>MiV4TTVO[~MV<[KT.OIOh6T [ V OT^VgOc[gOjTOV[VKVL`V.T:OL[/KTV[O T'[?O2V60TV[OL [gOfV^JdT^nTVO[hT6HcOG[.V<J,T V[OHVI[LT;OF(T*V[OOgT`Vf[iEi\TVO[vT/V9O<,T OV4EOgTf[gCgVgvTVO[^OLVD[.T9CTOV[(VgEjOc[gTgE(EFTO V[NET0C_O<[LV4>T"V[ORC V1TO.@][),[TVO:@dV^TaOc[c2Cg0E*E02:OT V[dT;V4[>OA CJTVO[~[KT.OI@fV<6T [ V Oz@"T^OcE[gVg>`&EHTOV[X>T:[/V./@f0OL /0 TV[O T'V6[?O20TV[O@-T^/@f[gOfEV^/-EHTVO[N@T6+u[.)vOGV<->] )-+ T V[OOFT;[LVI(T>V[O[iT`T"V[#O81:TO.[)V1,[TVOV^Oc[cTaE*ELOT V[dOA[>V4T;TTVO[~OIV<[KT.6T [ V OET^Vg[gOc+ E$"+ $TOV[0X+j7j[/#sOL$nT:V. $+a #TVO[|+[?O2T'V67 + TV[OT^Of9i[g-jV^#vE$n$-aE"#&TVO[^- OG[.T6V< -(T V[9 OT;OFVI[L(T*V[OT`OgVfE[i(E4TVO[vT/V9O<,T OV6Tf[gVgEOg(ENTVO[^[.OLVDT9,TOV[([gTgEVg#w$iOc+f0g$n$`+]E@$TO V[RT0V4[LO<>T"V[#OrV1T[)O.,[TVOV^OcTa[cE*ELOT V[dT;OA[>V4TTVO[~[KV<T.OI6T [ V OVg[gOcT^E&E+$+$T 0OV[h#wV.+jOL$n[/7iT: $+a#TV[O +[?T'V6O2 +7"TV[OT^Of#w$n-j9g[gV^E$-aE#6TVO[\- [.V<T6OG9-,T V[O[L))$5V16Y*e[)O.T *\"[TVO*6*V^7`[cTaOc+fE+]*ELO++T V7[dT;OA(i[>V4 (`JTVO[4`J( ($V<[KOI&c2^T.&[4"T [ V O`&&&$\E[g$bOcVg$d#kT^0a$#2E@$T $OV[80.`#qi$nV.OLT:[/+`0TV[O$$f#O2[?T'V60TV[OOf[gET^V^&EHTVO[hT6V<OG[.4T V[OOFT;VI[L(T*V[OT`OgE[iVf(E4TVO[vV9O<T/,T OV6OgVg[gTfE(ENTVO[*TVOLVD[.T9 VfT[ TOV[4OtOc$n[gVgETg#v$$E V:T #O V[R[LT0O<V4>T"V[OrV1[)TO.,[TVOT$nE#wOc[cTaV^ $TY[a#E2[OT V[d[>V4T;OATTVO[~0#u/V<OI[K$mT.$#/0T [ V O`T.[Vg[g$^OcT^-}#l]~+~EV$+-E# [ZT^VZ ]g,TOV[*+8V.[/OL+{T:-z-+TV[O $nV6#w$jO2*zT'+g@i@b[?+^$aTV[*O$EV^T^[gOf&EHT #VO[hT6[.OGV<*x4T *V[O[LOFVIT;(T*V[OT`[iEOg*Vf(E*TVO[vV9T/O<,T OV6E[gTfVg*Og(E+$ *@@+$,TVO[^T9+jGi$nOL[.#rGjVD $# T+aOV[+ [g*ETgOcVg+EGG*8TO V[R#wHjT0$nV4-j[LHjO<-a $*#T"V[OrTV1[)*O.&--[T*VOHHOcV^E[cTa*ELOT V[dT;*V4OA[>6*TVO[~V<[KT.OI6T [ V OVg[gEOcT^*&E*:TOV[hT:[/V.OL0TV[O *V6@g$a[?O2$j+g#wT'$n+^,T*V[O$EOf[gV^T^&EF#TVO[h*[.T6OGV<.*T V[OVIOFT;[L(T*V[O*ET`[iVfOg(E*"TVO[vO<T/V9,T OV6EOg[gTfVg*&+E+$$*>TVO[0@.[.VD+jOL$l#vGiT9 $+a#TOV[LV[]@+Oc[gE*VgTg+GE*>TO V[RO<V4$n[L-j-a#wT0Hi$$T#V[Op--T[)*O.V1H[T*VO0`V^0iETaOc[cL^*ELOT V[<00$[>J]/]T;*OAV4/f L,*TVO[B//8-V-^OIHaV<[KT.J T [ V OH--DH+\[gOcG^T^Vg#r*E+d$h$#E *>TOV[++"G2)i$jOLT:Eg#vV.[/)`*T$V[O#[?T'V6O2*0TE*)) V[O)` EOf[g)iEiT^V^&EHTVO[&) )E*[*V<[.T6OGFY*c4T* V[Of*+^*FGYOFVI[LT;+g(T*V[O++*GFT`Ca[iOg(`$bE(i*Vf#v$E *#TVO[N(((AaO<&^V9T/&V CT OVl&&6A $R$cTf#o[g@cOgEVg*$Z$#E*2$$ TVO@[^[.#wVDiT9$nOL>c`TOV[<$l#Vg*[gTgOcE(E*6TO V[RT0O<[LV4>T"V[Or*O.V1T[),[TV*OTaV^E[cOc*ELOT V[dOAT;[>*|V44* TVO[~V<OI[KT.6T [ V OT^Oc*[gEVg&E*8TOV[hT:OL[/V.0TVO[#w$m,$L#V6*O2T'[?0T*V[OOf[gET^V^&EHTVO[h[.OGV<*T64T* V[O#wOF[LVI$lT;$T#V[OEVf*Og[iT`(E *(TVO[vV9O<#q$iT/$#T OV6*Tf[g$nEVg#kOg$E*#@TVO[^VDOL[.T9,TOV[][VTO`iV`[d1zT\$mOc$$>x1$j9J^$z9^Ob$n4H`>$4~0//0L0m/{./0,J$e-$ C]-H$i$`)++)T)$l+$&)+lHTV[OC>aFC$v:g:`"g1|RO5a $T0B@^0:27a"H71$t5P"g$5H5Mj.a:e&v> &:".:JMZ"g7[Jjb">FF7R"gLjHC$v5NJTT@@a":Cj&|.c7@&<H\:j4.lH8:C@j7^&~.i&J7&~5V&.z@58@TJC:g$vAj"h$VPAa:a>a@A@h: @@Aj7d"67""c$v5O $"ACj A:>85*" &}.a:e &CJ@j"e .*:""Jj$7a@aCj7^7j$v:j"a $>C:@7C<:",&~@j.a &fL:iAj@:.|:2A"c&~7^Cj&(7" C5V&r$ZDj&>XX5@&D&d9Ej[$@E[JVNHES\78C@Bj$vJjE\>[ $EPNSJPNJGg@>B(G ;gJjx9>BE.; J(f9O$vLj $P9|(L>jNj&~4c &PNLj(i>>4L(;iJjJ N; E6JPj(j9L$v;aD[G\G\@^$PTL\@<9(^>jP>>(g>gLj00(>*L ;Z&`GjZ;0$n>j $ 0z&L>#g/~&v &/V@j-*-#>+^&v&+>&vd)&G)@;DG P@LG@< g$nQj1z;g($;aDP@VG[61*;Q&@> "G;D@.&t3Pj _;j;SDT@BGR3.&4;@GD>!gLj$n3y=g;P $3=aEXIS@@^*LPj$n3t == I@3E$!PLj!c3i=_=aIT@VEV3@L Qj&p3==IE@3 !&=aBaFP3oIT$f=cLj"c&$Q3"L3q$nB=IF=3&$FV=[B[IY Nj=_3q"g03 @xB=FI&N3Lj&r$= 3&"&|?[G[3t$l#f?gBKKG@ $3n# ?KLBG? Kj$n3o?a#]B)GO?[KS"3&$K3gIj$3L&vGj3I$3@&?J#GBGEj$i3j?K"$3E$Dj3g$n h 3 DP;a@VG[2$;ix3\Gj;D 32@6 *G;D@.3Lj&t;f a;SDTG@BGR&3<&;@GD, L!fJj3q$h;=aEXIS@@^3$&=eJ^Ij$n3c = I@E!3=$~!gLj=c3g=aIT@VIEV03L&jQj3=IE@ !=$3&Ba=aFPOj$hIT"g=eQ$H3$30"O 3q$jRjB==IF6$ 3 FV=[B[IYR=eNj3n"g:@3dB=FI"N3&mIj=4& 3?[G[#Y?g$h$BKKG@LI>?KBG?"Kj?T$nB)GO?[KS$#:/Gj'S0 K 0/4G'/tBj-&u*X -/&X*BG)$n&t+a+?K&$)+?B +*$n;i1|,eDj*;aDP@VG[1$X;&@T, G;D@.,e;i&t3;SDT@BGR3:&0D;@GD,,-f?j$l3r ;$EX=aIS3@^@6=ch?3l@j$n = I@=E3$- -f3qBj @=aIT@VEV 3T=anB Dj3&v=IE@ =3& -FPBa=a.e3r$hIT$D3(Fj=ex3n$n.B=IF=3$FB[FV=[IY =e3q._Bj&3@xB=FI(B&v3=j. =32&d=.?[G[?g$l/dFj3q$BKKG@3V/2?K?F BG&/^Gj?j$n3vGOB)?[KS3$@G Fj3`3*?/F-c3Gj&t3&6GBG&h$bIj3t?3K$&-I1|$nLj@j(j&uXDW@[G]L]Xd$&$1~X*(@DG@LLX)+P)+Jj>j9&u*e$n9BYEYJ^>^Vi$V&V0J BE>*>V$J/-B-/>\G\EX;a;j$n+j&vGj4SdJaQ^SB$h&~@P4.2>;2EGR0z.0J-{N-"00r/y*/N+$i<$+ -//-v+})w )+X)+$jSQ $+ ;+)G$JS2XXjIQ@`1|@j-j$nL^&mE^ @2&$$1BXX@L-@XIE>(&u&"(4>^C^G[J^$n9{/j&v>j*VdV$&9$CJ>GV/ V>@(&u&"(9a>]C^G[$n4&v0j S$Sc$&l4J^O^CWLgRJLOJT$mLLOK$8LJOLBO9J@*JOLlC @J$jJgO^LiOd$$J9C> GDJLO2O,L@J<$n6O JL$SUJ\OKLSJV,OLJ~SJ.GQOU LiJd&v(Of*&4JL O"(`$iO?J=L>*$LO J6LOJTO;(O JL8JfO^Lg08OG6OJLO^L"J.O.34]Lj$n&m-&JLO&-3 $\46LORLgJ^LOJfJjO9LFJI$f4d3t&g&3O$LJ&J Gj2dLL3tOGJU&v$n4$3 O$LJl&0GHjLIJNO>(OLJBS^H2JjJgOg3x0cLg/$n/JLO$$J.J"OKjL&(JLOl3:KO^LjLiJdx0JLOfHjO?LAJ=-aL(OJLJ-bO7LLJPCjHOLJ*C-gOcAjJcLiJLOA ?j-&?+^L.0J/O*@\0&JOL8-+xJULTOK$hCj@$ JL O+- +NC6O`LgJc>j(g//JLO.(*>$hJ2O";j&^L/2O$JL4;&!]$WLD.$LJO / Sp!H&vOdJj)Jj1x$nLj+$i>V@\7`C[X&$Lj&@:+)1l7>@ C~L OJJ0$X&jQiLjNjLj&t9}$m9a[LBY@VE`@$ &ZNe99E@B&NLZQN(L00B06-tP- /}/v++\-}4-D)~`)/$m/ $:j$n(I8L&v1|/G@L][BaDT;X@V 8Y"8R ;P][dXh&h$l@18B@D8 ;>@8(/\@[r($s$@i[$8;:Fd"X*@@@@@@/c:\windows\media\themic~1.wavc:\windows\media\tada.wavc:\windows\media\chord.wavc:\windows\media\chimes.wavc:\windows\media\zion.wavc:\windows\media\whitetre.wavc:\windows\media\whiteclo.wavc:\windows\media\sunsetrk.wavc:\windows\media\sunsetbg.wavc:\windows\media\stream.wavc:\windows\media\seasnake.wavc:\windows\media\rockgras.wavc:\windows\media\musicaop.wavc:\windows\media\themic~1.wavc:\windows\media\tada.wavc:\windows\media\ding.wavc:\windows\media\chord.wavc:\windows\media\chimes.wavc:\windows\media\zion.wavc:\windows\media\whitetre.wavc:\windows\media\whiteclo.wavc:\windows\media\sunsetrk.wavc:\windows\media\sunsetbg.wavc:\windows\media\stream.wavc:\windows\media\seasnake.wavc:\windows\media\rockgras.wavc:\windows\media\musicaop.wavc:\windows\media\themic~1.wavc:\windows\media\zion.wavc:\windows\media\whitetre.wavc:\windows\media\whiteclo.wavc:\windows\media\sunsetrk.wavc:\windows\media\sunsetbg.wavc:\windows\media\rockgras.wav'>Oas0ARct /@Qbs":P 4b|*R".'+Th-:1h3\5"8rX<@BDxFG JOS*X]b.d0^f8i\j?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~ibing of psychotropic medications. At the end of the presentation, you should have a global overview of some of the factors that drive the prescribing of medication along with an idea of what factors are important in selecting psychotropic medication. It is hoped that this information will be of value to you in communicating with primary care doctors or psychiatrists and in understanding decision making around psychotropic medication. These are the answers to the questions that you will have to correctly complete in order to obtain continuing education credit for the presentation. 1) The trend is one of increasing utilization of psychotropic medications; 2) When selecting anti-depressants, the SSRI type are generally utilized first and the traditiona TCA's or Tri Cyclic Antidepressants are generally utilized last; 3) Whereas there had really only been one mood stabilizer for a considerable number of years, we now have more choices; 4) The trend in prescribing of anti-psychotics is to move toward Atypical Antipsychotics; and 5) When having to prescribe anxiolytics, the trend is toward non-addicting types when ever it is appropriate. The overal trend is toward an increase in the prescribing of psychotropic medication. The reasons for the increase are the availability of more medications which are effective, safer medications which decrease the risk of mobidity or fatality from overdose, the increasing comfort level of primary care doctors in the prescribing of psychotropic medication, the decreased stigma in taking psychotropic medication along with an enhanced awareness of the benefits that can accrue from these medications, and finally new imaging techniques are confirming the foundation of psychiatric illness is in biology and that this disorders represent abnormal biological functioning of the brain -- not a weakness of character. A